Jonathan Brammer
Organization
Trials
Phase 2, Recruiting, 44 people, Jan 21, 2026
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Phase 2, Recruiting, 30 people, Oct 24, 2022
Sources: clinicaltrials.gov
Organization
Phase 2, Recruiting, 44 people, Jan 21, 2026
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Phase 2, Recruiting, 30 people, Oct 24, 2022
Sources: clinicaltrials.gov